Molecular diagnostics company Immunexpress on Tuesday announced the launch of its SeptiCyte Rapid EDTA (ethylenediaminetetraacetic acid)-anticoagulated blood compatible cartridges for the European market.
SeptiCyte Rapid is a sample-to-answer, cartridge-based, molecular test for sepsis that uses reverse transcription polymerase chain reaction (RT-PCR) to quantify the relative expression levels of host response genes isolated from whole blood.
The updated SeptiCyte Rapid cartridge adds undiluted EDTA-anticoagulated blood as a validated sample type.
EDTA-anticoagulated blood collection tubes are used routinely in clinical settings for hematology procedures around the world, Immunexpress noted.
The SeptiCyte Rapid EDTA-anticoagulated blood compatible cartridges will be sold in Europe by Immunexpress distribution partner Biocartis.
Validation of the updated SeptiCyte Rapid cartridge for the U.S. market is underway, with U.S. Food and Drug Administration studies expected to be complete in Q4 2022.